Table 1.
Clinical efficacy of selected novel agents for relapsed/refractory T-cell lymphoma
| Agents | Disease subtype | No of Pts | ORR (%) | CR rate (%) | Median PFS (months) | Median DoR (months) | References |
|---|---|---|---|---|---|---|---|
| Brentuximab vedotin | ALCL | 58 | 86 | 57 | 20 | 12.6 | Pro et al (2012)13 |
| CD30-positive PTCL | 34 | 41 | 24 | 2.6 | 6.7 | Horowitz et al (2014)14 | |
| CD30-positive CTCL | 64 | 67 | 16 | 16.7 | 16.7 | Prince et al (2017)15 | |
| Vorinostat | CTCL | 74 | 30 | NA | 4.9 | 5.6 | Mann et al (2007)21 |
| Romidepsin | CTCL | 71 | 34 | 5 | NA | 13.7 | Piekarz et al (2009)9 |
| CTCL | 96 | 38 | 1 | 8 | 15 | Whittaker et al (2010)10 | |
| PTCL | 130 | 25 | 15 | 4 | 28 | Coiffier et al (2014)11 | |
| Belinostat | PTCL | 120 | 26 | 11 | 1.6 | 13.6 | O’Connor et al (2015)22 |
| Chidamide | PTCL | 79 | 28 | 14 | 2.1 | 9.9 | Shi et al (2015)16 |
| Pralatrexate | PTCL | 111 | 29 | 11 | 3.5 | 10.1 | O’Connor et al (2011)8 |
| Mogamulizumab | CCR4-positive PTCL/CTCLa | 37 | 35 | 14 | 3 | NA | Ogura et al (2014)18 |
| CCR4-positive PTCL | 35 | 11 | 3 | 2 | 2.8 | Zinzani et al (2016)19 | |
| CTCL | 38 | 37 | 7.9 | 11.4 | 10.4 | Duvic et al (2015)20 | |
| Forodesine | PTCLa | 41 | 24 | 10 | 1.9 | 10.4 | Shibayama et al (2017)42 |
| CTCL | 101 | 11 | 0 | NA | 6.4 | Dummer et al (2014)39 |
Note:
a
Refractory patients were not included in these studies.
Abbreviations: ALCL, anaplastic large cell lymphoma; CCR4, CC chemokine receptor 4; CR, complete response; CTCL, cutaneous T-cell lymphoma; DoR, duration of response; NA, not available; ORR, overall response rate; PTCL, peripheral T-cell lymphoma; Pts, patients; PFS, progression-free survival.